J-L Yang1, X-J Qu, P J Russell, D Goldstein. 1. Department of Surgery, Prince of Wales Hospital, University of New South Wales, Sydney, Australia.
Abstract
BACKGROUND AND AIM: The biology of growth factor receptor expression has implications for receptor specific cancer therapy. In this study, we examined: (a) regulation of epidermal growth factor receptor (EGFR) expression in a panel of 10 human colon cancer cell lines using interferon alpha (IFN-alpha); (b) ability of IFN-alpha to inhibit cell proliferation; and (c) sensitivity of IFN-alpha pretreated cells to EGF. METHODS: Cell proliferation was measured both by crystal violet colorimetric and clonogenic assays. Cell surface, intracellular, and/or total cell protein expression of EGFR was assessed by indirect immunofluorescence flow cytometry and/or fluorescein isothiocyanate (FITC)-EGF binding and internalisation flow cytometric assay. RESULTS: IFN-alpha treatment upregulated expression of cell surface EGFR in seven of 10 colon cancer cell lines within 16 hours, reaching a peak within 48-96 hours; this was accompanied by transient elevation of intracellular EGFR and marked growth inhibition. IFN-alpha treated cancer cells were still sensitive to EGF proliferative stimulation. CONCLUSIONS: Our results indicate that cytostatic concentrations of IFN-alpha can enhance cell surface and intracellular EGFR expression in a proportion of human colon cancer cells. The antiproliferative action of IFN-alpha could not block the signal transduction of the EGF-EGFR pathway. This may have clinical implications for improving treatment based on targeting of EGFR.
BACKGROUND AND AIM: The biology of growth factor receptor expression has implications for receptor specific cancer therapy. In this study, we examined: (a) regulation of epidermal growth factor receptor (EGFR) expression in a panel of 10 humancolon cancer cell lines using interferon alpha (IFN-alpha); (b) ability of IFN-alpha to inhibit cell proliferation; and (c) sensitivity of IFN-alpha pretreated cells to EGF. METHODS: Cell proliferation was measured both by crystal violet colorimetric and clonogenic assays. Cell surface, intracellular, and/or total cell protein expression of EGFR was assessed by indirect immunofluorescence flow cytometry and/or fluorescein isothiocyanate (FITC)-EGF binding and internalisation flow cytometric assay. RESULTS:IFN-alpha treatment upregulated expression of cell surface EGFR in seven of 10 colon cancer cell lines within 16 hours, reaching a peak within 48-96 hours; this was accompanied by transient elevation of intracellular EGFR and marked growth inhibition. IFN-alpha treated cancer cells were still sensitive to EGF proliferative stimulation. CONCLUSIONS: Our results indicate that cytostatic concentrations of IFN-alpha can enhance cell surface and intracellular EGFR expression in a proportion of humancolon cancer cells. The antiproliferative action of IFN-alpha could not block the signal transduction of the EGF-EGFR pathway. This may have clinical implications for improving treatment based on targeting of EGFR.
Authors: D W Leaman; S Pisharody; T W Flickinger; M A Commane; J Schlessinger; I M Kerr; D E Levy; G R Stark Journal: Mol Cell Biol Date: 1996-01 Impact factor: 4.272
Authors: G Scambia; P B Panici; G Ferrandina; F Battaglia; G Sica; F Coronetta; C Rumi; S Mancuso Journal: Int J Cancer Date: 1994-09-15 Impact factor: 7.396
Authors: M Caraglia; A Leardi; S Corradino; F Ciardiello; A Budillon; R Guarrasi; A R Bianco; P Tagliaferri Journal: Int J Cancer Date: 1995-05-04 Impact factor: 7.396
Authors: Nichole E M Kaufman; Qianli Meng; Kaitlin E Griffin; Sitanshu S Singh; Achyut Dahal; Zehua Zhou; Frank R Fronczek; J Michael Mathis; Seetharama D Jois; M Graça H Vicente Journal: J Med Chem Date: 2019-03-25 Impact factor: 7.446
Authors: Tyrslai M Williams; Rushikesh Sable; Sitanshu Singh; Maria Graca H Vicente; Seetharama D Jois Journal: Chem Biol Drug Des Date: 2017-11-16 Impact factor: 2.817